{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T09:12:33Z","timestamp":1698484353933},"reference-count":38,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,3,25]],"date-time":"2008-03-25T00:00:00Z","timestamp":1206403200000},"content-version":"vor","delay-in-days":3950,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Australian and New Zealand Journal of Medicine"],"published-print":{"date-parts":[[1997,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p> <jats:italic>Background:<\/jats:italic> Advances in therapy and supportive care have improved the outlook for many patients with acute leukaemia, however elderly patients have increased treatment\u2010related toxicity and shorter survival. Most clinical trials have selected patient populations with young median ages and it is therefore difficult to apply results to the general population where the majority of patients presenting with acute leukaemia are over 60 years. There is little information in the literature guiding appropriate treatment of these patients.<\/jats:p><jats:p> <jats:italic>Aims:<\/jats:italic> To determine the relationship between age, treatment received, and outcome in patients presenting with acute leukaemia.<\/jats:p><jats:p> <jats:italic>Methods:<\/jats:italic> A retrospective analysis was performed on all patients presenting to Prince Henry's Hospital and Monash Medical Centre with acute myeloid leukaemia (AML) or acute lymphocytic leukaemia (ALL) during a five year period.<\/jats:p><jats:p> <jats:italic>Results:<\/jats:italic> Sixty\u2010six patients (51 \u2010 AML, 15 \u2010 ALL) presented with acute leukaemia between March 1989 and April 1994. Median patient age was 63 years; 32% of patients received supportive therapy only; 86% of patients with ALT, and 58% of patients with AML commencing remission\u2010induction chemotherapy entered a complete remission. Median survival for patients receiving only supportive therapy was three months. Median survival in patients under 55 years was almost twice as long as patients over 55 years receiving similar treatment (AML \u2010 eight <jats:italic>vs<\/jats:italic> four months <jats:italic>p<\/jats:italic>=0.023; ALL \u2010 3.5 <jats:italic>vs<\/jats:italic> seven months <jats:italic>p<\/jats:italic>=0.029).<\/jats:p><jats:p> <jats:italic>Conclusions:<\/jats:italic> Median survival for acute leukaemia is inversely proportional to age. Applying results from selected series to elderly patients with acute leukaemia is inappropriate.<\/jats:p>","DOI":"10.1111\/j.1445-5994.1997.tb01982.x","type":"journal-article","created":{"date-parts":[[2008,3,25]],"date-time":"2008-03-25T09:34:46Z","timestamp":1206437686000},"page":"301-306","source":"Crossref","is-referenced-by-count":4,"title":["Adult acute leukaemia \u2010 a retrospective study of 66 consecutive patients"],"prefix":"10.1111","volume":"27","author":[{"given":"J.","family":"Shapiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Stanley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Brodie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,3,25]]},"reference":[{"key":"e_1_2_1_2_2","volume-title":"Cancer in Victoria 1982\u20131987","author":"Giles G","year":"1992"},{"key":"e_1_2_1_3_2","volume-title":"Principles and practice of oncology","author":"Scheinberg D","year":"1997"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199410063311402"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199506223322503"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.1990.8.6.994","article-title":"Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard and high\u2010risk acute lymphoblastic leukaemia","volume":"8","author":"Kantarjian H","year":"1990","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_7_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1182\/blood.V73.1.57.57","article-title":"Treatment of acute lymphoblastic in adults with intensive induction, consolidation, and maintenance chemotherapy","volume":"73","author":"Hussein KK","year":"1989","journal-title":"Blood"},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood.V64.1.267.267","article-title":"Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukaemia: A prospective randomised trial by Cancer and Leukaemia Group B","volume":"64","author":"Gottlieb AJ","year":"1984","journal-title":"Blood"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(18)30258-2"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(88)90094-X"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb03256.x"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.9.1268"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870715)60:2<149::AID-CNCR2820600204>3.0.CO;2-F"},{"key":"e_1_2_1_14_2","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V60.2.454.454","article-title":"Cytarabine arabinoside with daunorubicin or Adriamycin for therapy of acute myelocytic leukaemia. A CALGB study","volume":"60","author":"Yates J","year":"1982","journal-title":"Blood"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830180206"},{"key":"e_1_2_1_16_2","first-page":"1203","article-title":"Treatment of acute myelocytic leukaemia: a study by Cancer and Leukaemia Group B","volume":"58","author":"Rai K","year":"1981","journal-title":"Am J Hematol"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.11.2002"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1992.tb00610.x"},{"key":"e_1_2_1_19_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood.V75.1.27.27","article-title":"Etoposide in acute nonlymphocytic leukaemia","volume":"75","author":"Bishop JF","year":"1990","journal-title":"Blood"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.264.8.1006"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199409051681"},{"key":"e_1_2_1_22_2","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1182\/blood.V87.5.1710.1710","article-title":"A randomised study of high\u2010dose cytarabine in induction in acute myeloid leukaemia","volume":"87","author":"Bishop JF","year":"1996","journal-title":"Blood"},{"key":"e_1_2_1_23_2","doi-asserted-by":"crossref","unstructured":"YoungJW PapadopolousEB CunninghamIet al.T\u2010cell depleted allogeneic bone\u2010marrow transplantation in adults with acute nonlymphocytic leukaemia in first remission.Blood1992;79\u20133380.","DOI":"10.1182\/blood.V79.12.3380.bloodjournal79123380"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199506223322504"},{"key":"e_1_2_1_25_2","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1200\/JCO.1984.2.8.865","article-title":"Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6\u2010thioguanine in the treatment of acute nonlymphocytic leukaemia in the elderly","volume":"2","author":"Kahn B","year":"1984","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199107183250305"},{"key":"e_1_2_1_27_2","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1182\/blood.V79.4.876.bloodjournal794876","article-title":"Intensive chemotherapy with mitoxantrone and high\u2010dose cytosine arabinoside followed by granulocyte\u2010macrophage colony stimulating factor in the treatment of patients with acute lymphocytic leukaemia","volume":"79","author":"Kantarjian HM","year":"1992","journal-title":"Blood"},{"key":"e_1_2_1_28_2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/blood.V86.2.457.bloodjournal862457","article-title":"A randomised placebo\u2010controlled phase III study of granulocyte\u2010macrophage colony stimulating factor in adult patients (55 to 70 years of age) with acute myelogenous leukaemia: a study of the Eastern Cooperative Oncology Group","volume":"86","author":"Rowe JM","year":"1995","journal-title":"Blood"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199506223322511"},{"issue":"1","key":"e_1_2_1_30_2","first-page":"S28","article-title":"The role of prognostic factors in acute myeloid leukaemia","volume":"10","author":"Buchner T","year":"1996","journal-title":"Leukemia"},{"issue":"3","key":"e_1_2_1_31_2","first-page":"S5","article-title":"More individual markers are necessary for patients with acute myeloid leukaemia (AML). Does cytomorphology or cytogenetics define the biological entity?","volume":"10","author":"Haferlach T.","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1993.tb04622.x"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1345"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)92674-7"},{"key":"e_1_2_1_35_2","first-page":"1141","article-title":"Comparison of three remission induction regimens and two post induction strategies for the treatment of acute nonlymphocytic leukaemia: A Cancer and Leukaemia Group B study","volume":"69","author":"Preisler H","year":"1987","journal-title":"Blood"},{"key":"e_1_2_1_36_2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood.V59.2.334.334","article-title":"Moderate dose methotrexate, vincristine, asparaginase and dexamethasone for treatment of adult acute lymphocytic leukaemia","volume":"59","author":"Esterhay R","year":"1982","journal-title":"Blood"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1986.tb01115.x"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V72.2.567.567"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92103-M"}],"container-title":["Australian and New Zealand Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1445-5994.1997.tb01982.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1445-5994.1997.tb01982.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T20:10:58Z","timestamp":1698437458000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1445-5994.1997.tb01982.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,6]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1997,6]]}},"alternative-id":["10.1111\/j.1445-5994.1997.tb01982.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1445-5994.1997.tb01982.x","archive":["Portico"],"relation":{},"ISSN":["0004-8291"],"issn-type":[{"value":"0004-8291","type":"print"}],"subject":[],"published":{"date-parts":[[1997,6]]}}}